BR112013027222A2 - composição de liberação prolongada que contém peptídeos como ingrediente ativo - Google Patents

composição de liberação prolongada que contém peptídeos como ingrediente ativo

Info

Publication number
BR112013027222A2
BR112013027222A2 BR112013027222A BR112013027222A BR112013027222A2 BR 112013027222 A2 BR112013027222 A2 BR 112013027222A2 BR 112013027222 A BR112013027222 A BR 112013027222A BR 112013027222 A BR112013027222 A BR 112013027222A BR 112013027222 A2 BR112013027222 A2 BR 112013027222A2
Authority
BR
Brazil
Prior art keywords
active ingredient
composition containing
extended release
release composition
containing peptides
Prior art date
Application number
BR112013027222A
Other languages
English (en)
Other versions
BR112013027222B1 (pt
Inventor
Béatrice Hacher
Didier Nourrisson
Faïza Laredj
Jeremiah Harnett
JOëL RICHARD
Laurent Bertocchi
Marie-Madeleine Baronnet
Nathalie Mondoly
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of BR112013027222A2 publication Critical patent/BR112013027222A2/pt
Publication of BR112013027222B1 publication Critical patent/BR112013027222B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Abstract

abstract not avaible
BR112013027222-8A 2011-06-14 2012-06-13 Composição de liberação sustentada que contém peptídeos como ingrediente ativo BR112013027222B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11290270.5 2011-06-14
EP11290270 2011-06-14
PCT/IB2012/001588 WO2012172433A2 (en) 2011-06-14 2012-06-13 A sustained-release composition containing peptides as active ingredient

Publications (2)

Publication Number Publication Date
BR112013027222A2 true BR112013027222A2 (pt) 2016-12-27
BR112013027222B1 BR112013027222B1 (pt) 2022-07-12

Family

ID=44851715

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013027222-8A BR112013027222B1 (pt) 2011-06-14 2012-06-13 Composição de liberação sustentada que contém peptídeos como ingrediente ativo

Country Status (14)

Country Link
US (1) US9415012B2 (pt)
EP (1) EP2720684B1 (pt)
JP (1) JP6072020B2 (pt)
KR (1) KR102038677B1 (pt)
CN (1) CN103608003B (pt)
AU (1) AU2012270024B2 (pt)
BR (1) BR112013027222B1 (pt)
CA (1) CA2833676C (pt)
ES (1) ES2718655T3 (pt)
HK (1) HK1194996A1 (pt)
MX (1) MX341642B (pt)
RU (1) RU2633483C2 (pt)
UA (1) UA114088C2 (pt)
WO (1) WO2012172433A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2797615T (pt) 2011-12-29 2019-07-11 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos
EP2705835A1 (en) * 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
KR102378943B1 (ko) * 2013-03-15 2022-03-25 리듬 파마슈티컬즈, 인코포레이티드 약학적 조성물
EP3450449A3 (en) 2013-03-15 2019-06-12 Rhythm Pharmaceuticals, Inc. Peptide compositions
CA3056614C (en) 2017-03-15 2023-09-26 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
EA202092275A1 (ru) * 2018-03-23 2021-02-09 Палатин Текнолоджиз, Инк. Составы пептидов, специфичных к рецептору меланокортина, и способы доставки в желудочно-кишечный тракт

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB761061A (en) 1952-06-21 1956-11-07 Leo Ab Method for producing preparations with protracted acth-effect and such preparations
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US7276251B2 (en) 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CA2318152A1 (en) * 1998-01-29 1999-08-05 Poly-Med Inc. Absorbable microparticles
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
HUE037147T2 (hu) * 2005-07-08 2018-08-28 Ipsen Pharma Melanokortin-receptor ligandumai
US8563000B2 (en) 2007-05-25 2013-10-22 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
US20100173834A1 (en) 2007-06-15 2010-07-08 Zheng Xin Dong Cyclic peptide melanocortin receptor ligands
TR201815292T4 (tr) * 2007-11-05 2018-11-21 Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College İnsüli̇n duyarliliğinin tedavi̇si̇nde melanokorti̇nleri̇n kullanimi.
JP5841708B2 (ja) 2008-07-01 2016-01-13 日東電工株式会社 表面被覆微粒子の医薬組成物
CN106139123A (zh) * 2009-08-05 2016-11-23 爱力根公司 脂质运载蛋白突变蛋白的控制释放制剂
CA2769883A1 (en) 2009-08-05 2011-02-10 Ipsen Pharma S.A.S. Use of melanocortins to treat dyslipidemia
US9314509B2 (en) * 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands

Also Published As

Publication number Publication date
JP6072020B2 (ja) 2017-02-01
JP2014517030A (ja) 2014-07-17
KR20140041531A (ko) 2014-04-04
CA2833676A1 (en) 2012-12-20
UA114088C2 (xx) 2017-04-25
WO2012172433A3 (en) 2013-01-31
MX2013013691A (es) 2014-03-05
RU2633483C2 (ru) 2017-10-12
KR102038677B1 (ko) 2019-10-30
US9415012B2 (en) 2016-08-16
EP2720684B1 (en) 2019-01-16
BR112013027222B1 (pt) 2022-07-12
US20140127303A1 (en) 2014-05-08
RU2014100909A (ru) 2015-07-20
AU2012270024B2 (en) 2016-12-22
EP2720684A2 (en) 2014-04-23
MX341642B (es) 2016-08-29
CN103608003A (zh) 2014-02-26
CN103608003B (zh) 2016-05-04
CA2833676C (en) 2019-04-23
ES2718655T3 (es) 2019-07-03
AU2012270024A1 (en) 2014-01-16
HK1194996A1 (zh) 2014-10-31
WO2012172433A2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
BR112014001219A2 (pt) perfume
UY34414A (es) Composiciones hemostáticas
DK2912074T3 (da) Dermal injicerbar steril sammensætning
UY34228A (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9
CR20150271A (es) Peptidos como agonistas de oxitocina
IN2015DN03029A (pt)
UY34092A (es) Nuevos compuestos como inhibidores de jak
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
BR112013028512A2 (pt) cápsula
UY33906A (es) Composiciones herbicidas que comprenden topramezona
BR112015012907A2 (pt) composição de cuidado pessoal
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
UY34415A (es) Composiciones hemostáticas
DOP2013000307A (es) Antagonistas de trpv4
BR112013025866A2 (pt) formulações com viscosidade reduzida
BR112014003027A2 (pt) formulação herbicida melhorada
CO6852077A2 (es) Composiciónes que comprenden ditiínas sustituidas fungicidas y compuestos activos adicionales
ECSP14033284A (es) Composición herbicida que tiene actividad herbicida mejorada
CO7151499A2 (es) Formulación inyectable
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
UY34158A (es) Composicion herbicida
BR112013026462A2 (pt) protetor de pé
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.